According to the latest financial results, Fischer Medical Ventures delivered exceptional annual performance with consolidated net profit of ₹30.97 crore (₹3,096.51 lakh) for FY26, representing a remarkable 2,463.64% increase from ₹1.21 crore in FY25. The company's consolidated revenue from operations reached ₹308.58 crore compared to ₹110.70 crore in the previous financial year, demonstrating strong business expansion. The Board of Directors has recommended a final dividend of ₹0.05 per equity share for FY26, subject to shareholder approval at the upcoming Annual General Meeting. The company's earnings per share (basic) improved significantly to ₹0.48 from ₹0.02 in FY25, reflecting enhanced profitability across all key financial metrics.
For the quarter ended March 2026, Fischer Medical Ventures reported a consolidated net loss of ₹7.09 crore (₹709.78 lakh) compared to a profit of ₹1.30 crore (₹130.44 lakh) in the corresponding quarter of the previous year. Despite the quarterly loss, the company demonstrated strong revenue momentum with Q4 FY26 revenue from operations at ₹97.73 crore (₹9,773.04 lakh). The company's operating profit margin (OPM) improved to 1.02% from negative 5.08% in the previous year's quarter, indicating operational efficiency gains despite the quarterly profit reversal.
In a strategic move to strengthen internal controls and governance, the Board of Directors approved the appointment of S. Ramanand Aiyer & Co. as internal auditors for the financial year 2026-27, following the audit committee's recommendation. This decision underscores the company's focus on regulatory compliance, transparent disclosure to investors, and ongoing enhancement of its financial oversight framework. The company's total expenses for FY26 increased to ₹274.31 crore (₹27,430.55 lakh) from ₹109.48 crore (₹10,948.16 lakh) in FY25**, reflecting the scale of business expansion. During the quarter, Fischer Medical Ventures transferred its investment in Pellucidcare Health Innovations Pte Ltd to its wholly-owned subsidiary, Flynncare HealthCare Innovations Private Limited, making it a step-down subsidiary.
The company's standalone performance showed a net loss of ₹1.04 crore for FY26 and ₹0.89 crore for Q4 FY26, indicating the consolidated results were primarily driven by subsidiary performance. Historical stock performance shows 1-day returns of +1.82% and 5-day returns of +8.85%, while 1-month returns stand at +1.38%. The trading window for designated persons will remain closed until 48 hours after the declaration of financial results. The company's annual operating profit margin (OPM) improved to 3.00% from negative 13.96% in FY25, indicating significant operational efficiency gains and sustainable business model improvements. Fischer Medical Ventures, formerly Fischer Chemic Ltd, operates in the medical and healthcare sector from its base in the AP Medtech Zone in Visakhapatnam, with shares trading on both BSE and NSE. The company's current share price stands at ₹38.14 with a weekly volatility of 6%, showing stable performance over the past year.
